General Information

Mail: University of Houston
Cullen College of Engineering
E421 Engineering Bldg 2, Houston, TX 77204-4007
Map & Driving Directions (includes parking information)
Email: info [at] egr [dot] uh [dot] edu

News

Chemical Engineering Shines in National Rankings

Printer-friendly versionSend by emailPDF version

By: 

Toby Weber
Krishnamoorti
Krishnamoorti

The University of Houston Cullen College of Engineering boasts one of the nation’s top doctoral programs in chemical engineering. That’s according to the most recent evaluation of Ph.D. programs released by The National Academies’ National Research Council, widely considered the most sound and respected rankings in academia.

Based on data from 2005, the chemical engineering Ph.D. program placed 18th in the country in the NRC’s survey-based rating, which measures a program against standards set by members of its discipline. By this metric, the Department of Chemical and Biomolecular Engineering bested its counterparts at nearby institutions such as Rice University and Texas A&M, as well as at highly regarded universities from around the country, including Cornell, Penn State and Georgia Tech. The University of Texas at Austin was the only school in the region to rank higher.

The department fared even better in the NRC’s research activity evaluation, which factored in publications, citations, the percent of the faculty holding research grants, and recognition of scholarship as evidenced by honors and awards. In this category, the college’s chemical engineering Ph.D. program ranked 13th in the country.

“Though these rankings are a bit dated, they reveal the strength of this department,” said Ramanan Krishnamoorti, chair of chemical and biomolecular engineering at the Cullen College. “While I’m very happy with our performance, with the addition of outstanding faculty members and the growth we’ve undergone in recent years, I’m confident that today, we would rank even higher.”

Faculty: 

Department: 

Related News Stories

Researcher Publishes Paper on Engineered Antibody that Targets Acute Myeloid Leukemia

Almost 19,000 new cases of acute myeloid leukemia and 10,500 deaths from the blood and bone marrow cancer could strike Americans this year, according to the American Cancer Society. Chemotherapy, when used as primary treatment, is successful in about 65 percent of patients with the cancer, and remission rates vary depending on patients’ individual characteristics, according to the organization.

Upcoming Events / Seminars

Archived News